Clinical trials: Peritoneal Carcinoma
Fallopian Tube Cancer, Ovarian Cancer
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CT-2103 in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00017017
- Testing
- paclitaxel poliglumex
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006028
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 31 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Collecting samples of tissue from patients with cancer to study in the laboratory may help doctors predict how well patients will respond to treatment with certain chemotherapy drugs and plan the best treatment.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00897039
- Testing
- flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Southeastern Gynecologic Oncology
Fallopian Tube Cancer, Ovarian Cancer
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as carboplatin use different ways to stop tumor cells from dividing so they stop…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00028912
- Testing
- bortezomib, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004012
- Testing
- capecitabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor
International PPB/DICER1 Registry
PPB has strong genetic implications, with a unique set of conditions in an individual or their family, occurring mostly in childhood and adolescence.
- Conditions
- Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma
- Trial name
- NCT03382158
- Where
- United States
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Fallopian Tube Cancer, Ovarian Cancer
S9912 Combination Chemo in Stage III Ovarian Cancer,
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003896
- Testing
- cisplatin, liposomal doxorubicin, paclitaxel
- Where
- 104 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005026
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- 47 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent…
- Trial name
- NCT00003523
- Testing
- aminocamptothecin colloidal dispersion
- Where
- 65 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Rare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei
French National Registry of Rare Peritoneal Surface Malignancies
Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France.
- Conditions
- Rare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei, Peritoneal Mesothelioma, Desmoplastic Small Round Cell Tumor
- Trial name
- RENAPE (NCT02834169)
- Testing
- Non interventional
- Where
- 33 sites in France
- Volunteers
- 2,171 people
- Sponsor
- Hospices Civils de Lyon
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003322
- Testing
- cisplatin, paclitaxel, quality-of-life assessment
- Where
- 67 sites in United States, Canada
- Volunteers
- 384 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent or…
- Trial name
- NCT00005836
- Testing
- oxaliplatin
- Where
- 74 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Peritoneal Cancer
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity.
- Trial name
- NCT00461786
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT06295965
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Washington
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00023699
- Testing
- gefitinib
- Where
- 53 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded to previous treatment.
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00036751
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)